Motor neuron disease
Conditions
Interventions
SVF treatment group1:Dose group 1: Intravenous infusion of autologous fat derived vascular matrix fraction (SVF) 0.5 × 106/kg
SVF treatment group2:Dose group 2: Intravenous infusion of autologous fat derived vascular matrix fraction (SVF) 1 × 106/kg
SVF treatment group3:Dose group 3: Intravenous infusion of autologous fat derived vascular matrix fraction (SVF) 2 × 106/kg
Sponsors
Suzhou Science & Technology Town Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: ? Meets the clinical and neurophysiological diagnostic criteria for revised El Escorial motor neuron disease; ? There is no structural damage to the brain and cervical spinal cord, and there is no corresponding manifestation on neuroimaging; ? Forced lung capacity greater than 30%; ? At least have basic nutritional status, with a body mass index of at least 18.5kg/m2; ? The patient and/or family members sign on the informed consent form.
Exclusion criteria
Exclusion criteria: ? Severe medullary damage with forced lung capacity less than 30%; ? Malnutrition, with a body mass index less than 18.5kg/m2; ? Tracheostomy has been performed; ? Exclude patients with a history of mental illness (such as schizophrenia); ? Has a history of systemic diseases. For example, malignant tumors, cardiovascular diseases (including asymptomatic hypertensive heart disease, arrhythmia, ischemic heart disease), stroke, and abnormal coagulation function; ? Cervical spondylosis or other diseases indicated by neuroimaging that may cause clinical symptoms of ALS; ? Stimulate the presence of metal in the local area; ? Serious abnormalities in hearing and vision; ? Skull injury or loss; ? There are contraindications for magnetic resonance imaging examination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The ALS functional rating scale (ALSFRS-R) scores for neurological examination and revision were evaluated before and after treatment, as well as at 1 and 3 months after treatment.; | — |
Secondary
| Measure | Time frame |
|---|---|
| manual muscle strength,MMT;Comprehensive neurophysiological examination; | — |
Countries
China
Contacts
Public ContactJingwei Li
Suzhou Science & Technology Town Hospital
Outcome results
None listed